Lisa Ditchey, DO
Family Medicine · Akron, OHNPI 1750777231
Payments from drug & device makers
Across 254 payments — averaging $14.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$747
- Lilly USA, LLC$544
- Novo Nordisk$335
- AstraZeneca$255
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$227
- GSK$180
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,804100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $747 |
| Lilly USA, LLC | 38 | $544 |
| Novo Nordisk | 34 | $335 |
| AstraZeneca | 12 | $255 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $227 |
| GSK | 13 | $180 |
| Boehringer Ingelheim | 11 | $166 |
| Daiichi Sankyo Inc. | 7 | $135 |
| Pfizer | 7 | $133 |
| Merck | 7 | $115 |
| Amgen | 8 | $115 |
| Xeris Pharmaceuticals, Inc. | 4 | $70 |
| Astellas Pharma US Inc | 4 | $69 |
| Edwards Lifesciences | 2 | $69 |
| Dexcom, Inc. | 4 | $64 |
| Novartis | 4 | $62 |
| Bayer | 3 | $59 |
| Lexicon Pharmaceuticals, Inc. | 2 | $55 |
| Radius Health, Inc. | 3 | $53 |
| Dynavax Technologies Corporation | 4 | $49 |
| Phathom Pharmaceuticals, Inc. | 2 | $34 |
| Exact Sciences | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Bausch Health US, LLC | 1 | $22 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Gilead | 1 | $17 |
| Johnson & Johnson | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
How this compares
$3,804 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $50,154 |
| TrulicityDulaglutide | 36 | $38,628 |
| JardianceEmpagliflozin | 39 | $37,310 |
| FarxigaDapagliflozin Propanediol | 31 | $28,956 |
| EliquisApixaban | 25 | $23,638 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $21,036 |
| XareltoRivaroxaban | 13 | $17,047 |
| JanuviaSitagliptin Phosphate | 12 | $15,735 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $7,394 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,136 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $6,214 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 13 | $5,732 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $3,982 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $3,321 |
| Omeprazole | 244 | $3,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $335 | $50,15446 claims |
| Lilly USA, LLCTrulicity | $544 | $38,62836 claims |
| Boehringer IngelheimJardiance | $166 | $37,31039 claims |
| AstraZenecaFarxiga, Symbicort | $255 | $35,17049 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $180 | $28,17150 claims |
| PfizerEliquis | $133 | $23,63825 claims |
| Johnson & JohnsonXarelto | $14 | $17,04713 claims |
| MerckJanuvia | $115 | $15,73512 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $3,110305 claims |
| AbbVieSynthroid | $747 | $2,16644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Akron
- Vernon HershbergerAkron$41K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.